HALIFAX, March 8 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
(TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid
diagnostic solutions, announced today that it will participate in the US Food
and Drug Administration's (FDA) Blood Products Advisory Committee (BPAC)
meeting taking place on Friday, March 10, 2006 in Gaithersburg, Maryland. At
the public meeting, Hermes Chan, MedMira's president and COO will present the
company's solution for over-the-counter (OTC) home-use HIV tests to the BPAC.
"We believe that home HIV tests can bring many benefits to both consumers
and public health agencies in the US. More people will know their HIV status,
seek treatment sooner, and ultimately decrease the spread of HIV," said Hermes
Chan, president and COO, MedMira. "MedMira's solution provides a comprehensive
OTC home-use HIV testing system, with a specific focus on public safety and
customer value. Based on our experience in delivering OTC HIV tests to the
Hong Kong market, we know safety and value are keys to a successful system and
As the first rapid HIV test manufacturer in the world to launch an OTC
test to consumers in Hong Kong in 2005, MedMira has gained significant
experience in implementing, managing, and monitoring a system for home-use HIV
tests. The company's MiraCare(TM) Rapid HIV Antibody Test (MiraCare(TM) HIV)
is a highly accurate and reliable fingerstick whole blood test, based on
MedMira's unique flow-through technology platform. This platform is the basis
for all of MedMira's rapid tests including the FDA-approved Reveal(R) G2 Rapid
HIV-1 Antibody test (Reveal(R) G2) which has been sold in the US since 2003.
BPAC reviews and evaluates available data concerning the safety,
effectiveness, and appropriate use of blood products derived from blood and
serum or biotechnology which are intended for use in the diagnosis,
prevention, or treatment of human diseases, and, as required, any other
product for which the Food and Drug Administration has regulatory
responsibility, and advises the Commissioner of Food and Drugs of its findings
regarding the safety, effectiveness, and labeling of the products, on clinical
and laboratory studies involving such products, on the affirmation or
revocation of biological product licenses, and on the quality and relevance of
FDA's research program which provides the scientific support for regulating
MedMira is the leading global manufacturer and marketer of in vitro flow-
through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
(OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
Regions, in the People's Republic of China. MiraCare(TM) is sold through
MedMira's distributor network to pharmacies, hospitals and laboratories in the
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.